Portal is implementing a simplified approach to intracellular delivery, focused on accelerating advances in RNA, gene editing, and AI-driven discovery technologies. Portal is committed to ensuring broad accessibility of its platform to enable a variety of research and therapeutic applications. The company was founded by Armon Sharei, Ph.D., founder and former CEO of SQZ Biotechnologies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/05/24 | $5,000,000 | Pre-Seed |
10X Capital Conscience VC Pear Ventures  | undisclosed |
